Question 1

What amounts of KPV did the published studies use?

Accepted Answer

They fall into three categories of measurement, and the categories do not convert into one another. The first is a strength in a drop: a 2006 rabbit study used KPV at 1, 5 or 10 mg/ml, in drops of 30 microlitres, on the surface of the eye. The second is a concentration in a dish, where a 2025 study applied 50 μg/mL of KPV to human skin cells damaged by fine dust. A 2026 study used a higher figure on mouse fat precursor cells, reporting that 100 μg/mL KPV reduced Oil Red O staining intensity by approximately 55%, Oil Red O being a dye that marks stored fat. The 2006 rabbit study also ran a cell arm, exposing corneal cells to 0.1, 1 and 10 microM, a molar unit that counts molecules rather than weight. The third is a dose bound to a carrier, and the 2026 oral conjugate study reported enhanced efficacy even at a 20-fold lower dose than the free peptide in mice with colitis. That last figure is relative rather than absolute, and the absolute quantities in the carrier studies are inseparable from the particular carrier formulation.

Question 2

Who received those amounts?

Accepted Answer

Animals and cells, never a person, among the research behind this page. The eye-drop strengths went to rabbits whose corneal surface had been scraped away on purpose. The oldest experiments used mice whose ears had been inflamed with an irritant, injecting the tripeptide and measuring the swelling afterwards. Gut work used rats and mice given colitis by a chemical, such as the 2021 rat study of colitis induced by TNBS, an irritant placed in the bowel. The dish concentrations went to cell lines, including human HaCaT keratinocytes, a standard line of human skin cells. Every one of those subjects was otherwise healthy apart from the injury the researchers deliberately created, and none was a person selecting an amount independently. That is why none of these figures can be read as a starting point for anyone, and why we do not convert any of them.

Question 3

How was KPV administered in the studies?

Accepted Answer

By at least six different routes, and almost none of them resembles withdrawing a solution from a vial. In the earliest mouse work it was given by IP injections, IP meaning intraperitoneal, which is an injection into the abdominal cavity. In rabbits it went on the eye as drops. In rats with colitis it was delivered into the colon inside a gel, which the authors described as intracolonic administration. By mouth, it went in as nanoparticles wrapped in gel, as in a 2017 study using oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) in mice. In rats with mouth ulcers caused by chemotherapy, a gel was applied to the gum lining and adhered to the wound surface for 7 hours. On skin wounds in diabetic mice it sat in the bottom layer of a dressing, with KPV encapsulated in the bottom layer and a growth factor above it. The route altered the meaning of the amount every time, which is the principal reason these figures are not comparable.

Question 4

How often was KPV given, and for how long?

Accepted Answer

Briefly, in every study that specifies a duration. The rabbit eye study gave two drops four times in a day, for 4 days, starting at the moment of injury. That is the most detailed schedule in this literature, and it covers four days of an injury that closed over within three. The cell work ran on a scale of hours, with rabbit corneal cells exposed for 1, 6 and 24 h. Several carrier studies describe a release profile instead of a schedule, because the formulation determines the timing once it is administered. In one 2021 rat study, only 30% of KPV was released from the KPV/SH-PGA hydrogel within 20 min, followed by a sustained-release behavior. A gel that releases gradually over hours and a drop that is cleared within minutes represent different schedules even at identical strength, which is why frequency cannot be transferred from one study to another.

Question 5

Is there a KPV dosage chart?

Accepted Answer

Not one built from evidence, and the units explain why. A chart needs one kind of number for one kind of body, and the KPV record has three kinds for four kinds of subject. Drop strengths in milligrams per millilitre, dish concentrations in micrograms per millilitre or micromolar, and carrier doses expressed against the free peptide cannot sit in one column without inventing a conversion. The 2026 sport review describes the gap a chart would have to fill, noting that most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. A circulating chart for KPV therefore has no study behind its numbers among the research covered here. That is a statement about the provenance of the numbers rather than a judgement about anyone who holds one.

Question 6

Why is a study amount not a protocol?

Accepted Answer

Because each amount was chosen to answer a narrow question in one model, and it carries that model with it. The rabbit strengths were picked to test whether KPV changed how fast a scraped cornea closed, and the result was that the mean percent epithelial defect remaining each time was significantly smaller in animals treated with KPV. That identifies a strength that was effective on an injured rabbit eye. It does not tell you an amount for any other tissue or species. The carrier studies make the point more sharply, since the 2017 mouse work found its coated particles in gel showed a much better therapeutic efficacy than a simpler particle in gel, carrying the same peptide. The same amount of KPV did different things depending on the package, so the amount alone was never the variable that mattered. Animal amounts also do not scale to a person by body weight, and no validated conversion exists among these sources for this compound.

Question 7

Does more KPV mean a stronger effect?

Accepted Answer

Not reliably, and this is one of the more useful findings in the whole record. The 1991 mouse study reported that the dose-response relations exhibited the bell-shaped characteristics seen previously with MSH peptides. A bell-shaped curve means the effect climbs as the amount rises, peaks, and then falls away again at higher amounts. Other work found a straighter relation within a narrow range, as when a 2026 study reported that KPV treatment dose-dependently suppressed adipocyte differentiation, the step by which a precursor cell becomes a fat cell. In the rabbit cell arm, cell viability was stimulated by 1 and 10 microM concentrations, while the lowest strength tested was not reported as doing so. Read together, these say the relation between amount and effect depends on the model, and in the one animal model that mapped it fully, too much was weaker than enough.

Question 8

How much of a KPV dose reaches its target?

Accepted Answer

That depends almost entirely on the carrier, which is why the carrier studies exist at all. A 2026 paper frames the problem for every peptide swallowed, noting that oral delivery of peptide therapeutics remains challenging due to gastrointestinal (GI) degradation and poor intestinal absorption. Its own conjugate, proKPV, achieved a 3.8-fold greater colonic accumulation than free KPV in mice with colitis. A 2024 mouse study targeted PepT1, a transporter on gut cells that carries small peptides inward, building its particle around that route. The 2022 diabetic wound film staged its release so that KPV was firstly released within 3 day, ahead of the growth factor. So the amount placed in the animal and the amount that reached the tissue were different numbers in every design, and only the first is usually what gets quoted.

Question 9

How do you reconstitute a KPV vial, and how long does it keep?

Accepted Answer

The research behind this page does not describe reconstituting a vial, because none of the studies used one in that way. The arithmetic for any vial is the same for every peptide: the amount in the vial divided by the volume of water added gives the strength per millilitre, and the reconstitution calculator at the reconstitution calculator does that sum on figures you supply. What the research does say concerns stability once KPV is in water. A 2021 rat study reported that KPV solution is very unstable when rectally administered, compromising its therapeutic efficacy. In that rat study the gel improved matters, as the stability of KPV in the SH-PGA hydrogel was obviously enhanced after 2 h of exposure to body temperature. A 2022 gel was credited with retaining its bioactivity for a longer time under high temperature conditions, tested at 50 °C. How long a plain solution of KPV keeps in a refrigerator has not been measured among these sources, and the instability findings are a reason to treat that as unknown rather than assumed.

Question 10

Is there a cycle or a break in the published work?

Accepted Answer

No, and the reason is that no study among the research behind this page ran long enough to need one. Cycling means alternating periods on and off a compound, and it presupposes continuous exposure measured in weeks or months. The longest stated course among the research behind this page is the four days of rabbit eye drops, and the oldest mouse experiments read their result within hours of a single injection. The 2026 sport review files the whole class under experimental substances with poorly defined long-term risks, which is the opposite of a settled schedule. A cycle length or a washout period quoted for KPV is therefore not drawn from any study covered here. Whether repeated courses behave differently from a first one is a question the record has not been asked, rather than one it has answered either way.

Question 11

Is there an approved dose of KPV?

Accepted Answer

No. No approval for any use is recorded among the sources behind this page, so there is no label and no labelled amount to report. The nearest regulatory material is a 2026 analysis for compounding pharmacists, which examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders. An advisory review weighing whether pharmacies may prepare a class of peptides is not an approval of any amount. The bowel disease literature speaks of KPV in the conditional, with a 2023 review arguing that molecules interfering with the melanocortin system could represent new drugs for IBD, inflammatory bowel disease. Could represent is the language of a candidate, and a candidate has no dose until a trial in people sets one. What is documented about harm at any of these amounts is set out on the KPV safety page, and how the studied forms compare with each other is on the KPV comparison page.

Study	What was treated	Amount studied	Kind of measure
2006 rabbit study	Surface of the eye	1, 5 or 10 mg/ml, in 30-microlitre drops	Strength in a drop
2006 rabbit study, cell arm	Corneal cells	0.1, 1 and 10 microM	Molar concentration
2025 study	Human skin cells	50 μg/mL	Concentration in a dish
2026 study	Mouse fat precursor cells	100 μg/mL	Concentration in a dish
2026 oral conjugate study	Mice with colitis	20-fold lower than the free peptide	Relative, not absolute

KPV protocols in the published literature